LH

SEC source: 0000920148-24-000022 · primary_doc.xml · nonDerivative · entry 2

Schechter Adam H · CIK 0001376841 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 93,630

F2 · kind: Stock withholding to satisfy tax withholding obligations.

SEC source: 0000920148-24-000022 · primary_doc.xml · nonDerivative · entry 1

Schechter Adam H · CIK 0001376841 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 125,429

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Stock Unit ("RSU") represents the contingent right to receive one share of Laboratory Corporation of America Holdings ("Labcorp") Common Stock.

SEC source: 0000920148-24-000021 · primary_doc.xml · derivative · entry 3

DiVincenzo Jonathan P. · CIK 0001453524 · EVP, Pres, Central Labs & Intl

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,965

Underlying: Common Stock · 3,012 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the contingent right to receive one share of Laboratory Corporation of America Holdings ("Labcorp") Common Stock.

F1 · price: Each Restricted Stock Unit ("RSU") represents the contingent right to receive one share of Laboratory Corporation of America Holdings ("Labcorp") Common Stock.

F3 · derivative.exercise_date: As previously reported, in connection with the spin-off ("Spin-Off") of Fortrea Holdings Inc. ("Fortrea") by Labcorp, performance awards granted by Labcorp in 2021 for the 3-year performance period through December 31, 2023 (the "2021 PSA") were converted into time-vesting RSUs of Labcorp pursuant to the terms of the Employee Matters Agreement (the "EMA") by and between Labcorp and Fortrea. The 2021 PSA was converted into a number of time-vesting Labcorp RSUs, based on the degree of achievement of the performance criteria subject to the 2021 PSA prior to the Spin-Off and the final adjustment ratio applied to Labcorp equity awards in connection with the Spin-Off, calculated pursuant to the terms of the EMA, which fully vested on March 27, 2024.

F3 · derivative.expiration_date: As previously reported, in connection with the spin-off ("Spin-Off") of Fortrea Holdings Inc. ("Fortrea") by Labcorp, performance awards granted by Labcorp in 2021 for the 3-year performance period through December 31, 2023 (the "2021 PSA") were converted into time-vesting RSUs of Labcorp pursuant to the terms of the Employee Matters Agreement (the "EMA") by and between Labcorp and Fortrea. The 2021 PSA was converted into a number of time-vesting Labcorp RSUs, based on the degree of achievement of the performance criteria subject to the 2021 PSA prior to the Spin-Off and the final adjustment ratio applied to Labcorp equity awards in connection with the Spin-Off, calculated pursuant to the terms of the EMA, which fully vested on March 27, 2024.

F4 · balance_after: This number reflects the aggregate number of RSUs held by the reporting person.

SEC source: 0000920148-24-000021 · primary_doc.xml · nonDerivative · entry 2

DiVincenzo Jonathan P. · CIK 0001453524 · EVP, Pres, Central Labs & Intl

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,460.5491

F2 · kind: Stock withholding to satisfy tax withholding obligations.

SEC source: 0000920148-24-000021 · primary_doc.xml · nonDerivative · entry 1

DiVincenzo Jonathan P. · CIK 0001453524 · EVP, Pres, Central Labs & Intl

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,412.5491

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Stock Unit ("RSU") represents the contingent right to receive one share of Laboratory Corporation of America Holdings ("Labcorp") Common Stock.

SEC source: 0000920148-24-000019 · primary_doc.xml · derivative · entry 3

Summy Amy B. · CIK 0001805303 · EVP, Chief Marketing Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,317

Underlying: Common Stock · 5,778 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the contingent right to receive one share of Laboratory Corporation of America Holdings ("Labcorp") Common Stock.

F1 · price: Each Restricted Stock Unit ("RSU") represents the contingent right to receive one share of Laboratory Corporation of America Holdings ("Labcorp") Common Stock.

F3 · derivative.exercise_date: As previously reported, in connection with the spin-off ("Spin-Off") of Fortrea Holdings Inc. ("Fortrea") by Labcorp, performance awards granted by Labcorp in 2021 for the 3-year performance period through December 31, 2023 (the "2021 PSA") were converted into time-vesting RSUs of Labcorp pursuant to the terms of the Employee Matters Agreement (the "EMA") by and between Labcorp and Fortrea. The 2021 PSA was converted into a number of time-vesting Labcorp RSUs, based on the degree of achievement of the performance criteria subject to the 2021 PSA prior to the Spin-Off and the final adjustment ratio applied to Labcorp equity awards in connection with the Spin-Off, calculated pursuant to the terms of the EMA, which fully vested on March 27, 2024.

F3 · derivative.expiration_date: As previously reported, in connection with the spin-off ("Spin-Off") of Fortrea Holdings Inc. ("Fortrea") by Labcorp, performance awards granted by Labcorp in 2021 for the 3-year performance period through December 31, 2023 (the "2021 PSA") were converted into time-vesting RSUs of Labcorp pursuant to the terms of the Employee Matters Agreement (the "EMA") by and between Labcorp and Fortrea. The 2021 PSA was converted into a number of time-vesting Labcorp RSUs, based on the degree of achievement of the performance criteria subject to the 2021 PSA prior to the Spin-Off and the final adjustment ratio applied to Labcorp equity awards in connection with the Spin-Off, calculated pursuant to the terms of the EMA, which fully vested on March 27, 2024.

F4 · balance_after: This number reflects the aggregate number of RSUs held by the reporting person.

SEC source: 0000920148-24-000019 · primary_doc.xml · nonDerivative · entry 2

Summy Amy B. · CIK 0001805303 · EVP, Chief Marketing Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,475

F2 · kind: Stock withholding to satisfy tax withholding obligations.

SEC source: 0000920148-24-000019 · primary_doc.xml · nonDerivative · entry 1

Summy Amy B. · CIK 0001805303 · EVP, Chief Marketing Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,637

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Stock Unit ("RSU") represents the contingent right to receive one share of Laboratory Corporation of America Holdings ("Labcorp") Common Stock.

SEC source: 0000920148-24-000020 · primary_doc.xml · derivative · entry 3

Wilkinson Peter J · CIK 0001398138 · SVP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 791

Underlying: Common Stock · 3,079 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the contingent right to receive one share of Laboratory Corporation of America Holdings ("Labcorp") Common Stock.

F1 · price: Each Restricted Stock Unit ("RSU") represents the contingent right to receive one share of Laboratory Corporation of America Holdings ("Labcorp") Common Stock.

F3 · derivative.exercise_date: As previously reported, in connection with the spin-off ("Spin-Off") of Fortrea Holdings Inc. ("Fortrea") by Labcorp, performance awards granted by Labcorp in 2021 for the 3-year performance period through December 31, 2023 (the "2021 PSA") were converted into time-vesting RSUs of Labcorp pursuant to the terms of the Employee Matters Agreement (the "EMA") by and between Labcorp and Fortrea. The 2021 PSA was converted into a number of time-vesting Labcorp RSUs, based on the degree of achievement of the performance criteria subject to the 2021 PSA prior to the Spin-Off and the final adjustment ratio applied to Labcorp equity awards in connection with the Spin-Off, calculated pursuant to the terms of the EMA, which fully vested on March 27, 2024.

F3 · derivative.expiration_date: As previously reported, in connection with the spin-off ("Spin-Off") of Fortrea Holdings Inc. ("Fortrea") by Labcorp, performance awards granted by Labcorp in 2021 for the 3-year performance period through December 31, 2023 (the "2021 PSA") were converted into time-vesting RSUs of Labcorp pursuant to the terms of the Employee Matters Agreement (the "EMA") by and between Labcorp and Fortrea. The 2021 PSA was converted into a number of time-vesting Labcorp RSUs, based on the degree of achievement of the performance criteria subject to the 2021 PSA prior to the Spin-Off and the final adjustment ratio applied to Labcorp equity awards in connection with the Spin-Off, calculated pursuant to the terms of the EMA, which fully vested on March 27, 2024.

F4 · balance_after: This number reflects the aggregate number of RSUs held by the reporting person.

SEC source: 0000920148-24-000020 · primary_doc.xml · nonDerivative · entry 2

Wilkinson Peter J · CIK 0001398138 · SVP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,526.2194

F2 · kind: Stock withholding to satisfy tax withholding obligations.

SEC source: 0000920148-24-000020 · primary_doc.xml · nonDerivative · entry 1

Wilkinson Peter J · CIK 0001398138 · SVP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,420.2194

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Stock Unit ("RSU") represents the contingent right to receive one share of Laboratory Corporation of America Holdings ("Labcorp") Common Stock.

SEC source: 0000920148-24-000018 · primary_doc.xml · derivative · entry 3

EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,706

Underlying: Common Stock · 20,033 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the contingent right to receive one share of Laboratory Corporation of America Holdings ("Labcorp") Common Stock.

F1 · price: Each Restricted Stock Unit ("RSU") represents the contingent right to receive one share of Laboratory Corporation of America Holdings ("Labcorp") Common Stock.

F3 · derivative.exercise_date: As previously reported, in connection with the spin-off ("Spin-Off") of Fortrea Holdings Inc. ("Fortrea") by Labcorp, performance awards granted by Labcorp in 2021 for the 3-year performance period through December 31, 2023 (the "2021 PSA") were converted into time-vesting RSUs of Labcorp pursuant to the terms of the Employee Matters Agreement (the "EMA") by and between Labcorp and Fortrea. The 2021 PSA was converted into a number of time-vesting Labcorp RSUs, based on the degree of achievement of the performance criteria subject to the 2021 PSA prior to the Spin-Off and the final adjustment ratio applied to Labcorp equity awards in connection with the Spin-Off, calculated pursuant to the terms of the EMA, which fully vested on March 27, 2024.

F3 · derivative.expiration_date: As previously reported, in connection with the spin-off ("Spin-Off") of Fortrea Holdings Inc. ("Fortrea") by Labcorp, performance awards granted by Labcorp in 2021 for the 3-year performance period through December 31, 2023 (the "2021 PSA") were converted into time-vesting RSUs of Labcorp pursuant to the terms of the Employee Matters Agreement (the "EMA") by and between Labcorp and Fortrea. The 2021 PSA was converted into a number of time-vesting Labcorp RSUs, based on the degree of achievement of the performance criteria subject to the 2021 PSA prior to the Spin-Off and the final adjustment ratio applied to Labcorp equity awards in connection with the Spin-Off, calculated pursuant to the terms of the EMA, which fully vested on March 27, 2024.

F4 · balance_after: This number reflects the aggregate number of RSUs held by the reporting person.

SEC source: 0000920148-24-000018 · primary_doc.xml · nonDerivative · entry 2

EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,823

F2 · kind: Stock withholding to satisfy tax withholding obligations.

SEC source: 0000920148-24-000018 · primary_doc.xml · nonDerivative · entry 1

EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 43,628

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Stock Unit ("RSU") represents the contingent right to receive one share of Laboratory Corporation of America Holdings ("Labcorp") Common Stock.

SEC source: 0000920148-24-000017 · primary_doc.xml · derivative · entry 3

BERBERIAN LANCE · CIK 0001102900 · EVP, CIO & CTO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,100

Underlying: Common Stock · 7,697 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the contingent right to receive one share of Laboratory Corporation of America Holdings ("Labcorp") Common Stock.

F1 · price: Each Restricted Stock Unit ("RSU") represents the contingent right to receive one share of Laboratory Corporation of America Holdings ("Labcorp") Common Stock.

F3 · derivative.exercise_date: As previously reported, in connection with the spin-off ("Spin-Off") of Fortrea Holdings Inc. ("Fortrea") by Labcorp, performance awards granted by Labcorp in 2021 for the 3-year performance period through December 31, 2023 (the "2021 PSA") were converted into time-vesting RSUs of Labcorp pursuant to the terms of the Employee Matters Agreement (the "EMA") by and between Labcorp and Fortrea. The 2021 PSA was converted into a number of time-vesting Labcorp RSUs, based on the degree of achievement of the performance criteria subject to the 2021 PSA prior to the Spin-Off and the final adjustment ratio applied to Labcorp equity awards in connection with the Spin-Off, calculated pursuant to the terms of the EMA, which fully vested on March 27, 2024.

F3 · derivative.expiration_date: As previously reported, in connection with the spin-off ("Spin-Off") of Fortrea Holdings Inc. ("Fortrea") by Labcorp, performance awards granted by Labcorp in 2021 for the 3-year performance period through December 31, 2023 (the "2021 PSA") were converted into time-vesting RSUs of Labcorp pursuant to the terms of the Employee Matters Agreement (the "EMA") by and between Labcorp and Fortrea. The 2021 PSA was converted into a number of time-vesting Labcorp RSUs, based on the degree of achievement of the performance criteria subject to the 2021 PSA prior to the Spin-Off and the final adjustment ratio applied to Labcorp equity awards in connection with the Spin-Off, calculated pursuant to the terms of the EMA, which fully vested on March 27, 2024.

F4 · balance_after: This number reflects the aggregate number of RSUs held by the reporting person.

SEC source: 0000920148-24-000017 · primary_doc.xml · nonDerivative · entry 2

BERBERIAN LANCE · CIK 0001102900 · EVP, CIO & CTO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,014

F2 · kind: Stock withholding to satisfy tax withholding obligations.

SEC source: 0000920148-24-000017 · primary_doc.xml · nonDerivative · entry 1

BERBERIAN LANCE · CIK 0001102900 · EVP, CIO & CTO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,313

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Stock Unit ("RSU") represents the contingent right to receive one share of Laboratory Corporation of America Holdings ("Labcorp") Common Stock.

SEC source: 0001127602-24-009301 · form4.xml · derivative · entry 3

Schroeder Mark S · CIK 0001793112 · EVP, Pres Diagnostics & COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,119 shares

Expires 2027-02-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan.

F3 · derivative.exercise_price: Represents amounts automatically adjusted based on the final adjustment ratio applied to equity awards in connection with the spin-off of Fortrea Holdings Inc. ("Fortrea") by Laboratory Corporation of America Holdings ("Labcorp"), calculated pursuant to the terms of the Employee Matters Agreement by and between Labcorp and Fortrea.

F3 · shares: Represents amounts automatically adjusted based on the final adjustment ratio applied to equity awards in connection with the spin-off of Fortrea Holdings Inc. ("Fortrea") by Laboratory Corporation of America Holdings ("Labcorp"), calculated pursuant to the terms of the Employee Matters Agreement by and between Labcorp and Fortrea.

F4 · derivative.exercise_date: The option vested in three equal annual installments beginning on the date reflected in this column.

SEC source: 0001127602-24-009301 · form4.xml · nonDerivative · entry 2

Schroeder Mark S · CIK 0001793112 · EVP, Pres Diagnostics & COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,036.1426

F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

SEC source: 0001127602-24-009301 · form4.xml · nonDerivative · entry 1

Schroeder Mark S · CIK 0001793112 · EVP, Pres Diagnostics & COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 10,084.1426

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-24-009300 · form4.xml · nonDerivative · entry 1

Summy Amy B. · CIK 0001805303 · EVP, Chief Marketing Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,859

F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

SEC source: 0001127602-24-006253 · form4.xml · derivative · entry 6

EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 14,054 shares

Expires 2030-02-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan.

F6 · derivative.exercise_price: Represents amounts automatically adjusted based on the final adjustment ratio applied to equity awards in connection with the spin-off of Fortrea Holdings Inc. ("Fortrea") by Laboratory Corporation of America Holdings ("Labcorp"), calculated pursuant to the terms of the Employee Matters Agreement by and between Labcorp and Fortrea.

F6 · shares: Represents amounts automatically adjusted based on the final adjustment ratio applied to equity awards in connection with the spin-off of Fortrea Holdings Inc. ("Fortrea") by Laboratory Corporation of America Holdings ("Labcorp"), calculated pursuant to the terms of the Employee Matters Agreement by and between Labcorp and Fortrea.

F7 · derivative.exercise_date: The option vested in three equal annual installments beginning on the date reflected in this column.

SEC source: 0001127602-24-006253 · form4.xml · nonDerivative · entry 5

EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,595

F4 · price: The price of $217.9842 per share represents a weighted average of sales prices ranging from $217.89 to $218.075 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.

SEC source: 0001127602-24-006253 · form4.xml · nonDerivative · entry 4

EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,148

F3 · price: The price of $217.5205 per share represents a weighted average of sales prices ranging from $216.87 to $217.86 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.

SEC source: 0001127602-24-006253 · form4.xml · nonDerivative · entry 3

EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,813

F2 · price: The price of $215.6759 per share represents a weighted average of sales prices ranging from $215.80 to $216.66 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.

SEC source: 0001127602-24-006253 · form4.xml · nonDerivative · entry 2

EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,720

F1 · price: The price of $215.3661 per share represents a weighted average of sales prices ranging from $214.80 to $215.79 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.

SEC source: 0001127602-24-006253 · form4.xml · nonDerivative · entry 1

EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 58,099

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-24-006252 · form4.xml · nonDerivative · entry 1

DiVincenzo Jonathan P. · CIK 0001453524 · EVP, Pres, Central Labs & Intl

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,400.5491

F1 · price: The price of $215.4901 per share represents a weighted average of sales prices ranging from $215.46 to $215.55 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a securityholder of the issuer, full information regarding the number of shares purchased or sold at each separate price.

SEC source: 0001127602-24-005126 · form4.xml · nonDerivative · entry 1

van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,636.979

F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

SEC source: 0001127602-24-004643 · form4.xml · nonDerivative · entry 2

Schechter Adam H · CIK 0001376841 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 52,994

F2 · kind: Stock withholding to satisfy tax withholding obligations.

SEC source: 0001127602-24-004642 · form4.xml · nonDerivative · entry 2

EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,045

F2 · kind: Stock withholding to satisfy tax withholding obligations.

SEC source: 0001127602-24-004641 · form4.xml · nonDerivative · entry 2

DiVincenzo Jonathan P. · CIK 0001453524 · EVP, Pres, Central Labs & Intl

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,900.5491

F2 · kind: Stock withholding to satisfy tax withholding obligations.

SEC source: 0001127602-24-004640 · form4.xml · nonDerivative · entry 2

Caveney Brian J · CIK 0001717915 · EVP, Pres of ED, CMO & CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,386.0428

F2 · kind: Stock withholding to satisfy tax withholding obligations.

SEC source: 0001127602-24-004639 · form4.xml · nonDerivative · entry 2

BERBERIAN LANCE · CIK 0001102900 · EVP, CIO & CTO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,616

F2 · kind: Stock withholding to satisfy tax withholding obligations.

SEC source: 0001127602-24-004638 · form4.xml · nonDerivative · entry 2

Schroeder Mark S · CIK 0001793112 · EVP, Pres Diagnostics & COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,965.1426

F2 · kind: Stock withholding to satisfy tax withholding obligations.

SEC source: 0001127602-24-004637 · form4.xml · nonDerivative · entry 2

Summy Amy B. · CIK 0001805303 · EVP, Chief Marketing Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,086

F2 · kind: Stock withholding to satisfy tax withholding obligations.

SEC source: 0001127602-24-004636 · form4.xml · nonDerivative · entry 2

van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,873.979

F2 · kind: Stock withholding to satisfy tax withholding obligations.

SEC source: 0001127602-24-004635 · form4.xml · nonDerivative · entry 2

Wilkinson Peter J · CIK 0001398138 · SVP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,341.2194

F2 · kind: Stock withholding to satisfy tax withholding obligations.

SEC source: 0001127602-24-004643 · form4.xml · derivative · entry 3

Schechter Adam H · CIK 0001376841 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 95,277

Underlying: Common Stock · 2,964 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

F3 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 11, 2023.

F3 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 11, 2023.

F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person.

SEC source: 0001127602-24-004643 · form4.xml · nonDerivative · entry 1

Schechter Adam H · CIK 0001376841 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 54,225

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

SEC source: 0001127602-24-004642 · form4.xml · derivative · entry 3

EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,739

Underlying: Common Stock · 807 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

F3 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 11, 2023.

F3 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 11, 2023.

F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person.

SEC source: 0001127602-24-004642 · form4.xml · nonDerivative · entry 1

EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,260

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

SEC source: 0001127602-24-004641 · form4.xml · derivative · entry 3

DiVincenzo Jonathan P. · CIK 0001453524 · EVP, Pres, Central Labs & Intl

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,977

Underlying: Common Stock · 201 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

F3 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in two equal annual installments beginning on February 11, 2024.

F3 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in two equal annual installments beginning on February 11, 2024.

F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person.

SEC source: 0001127602-24-004641 · form4.xml · nonDerivative · entry 1

DiVincenzo Jonathan P. · CIK 0001453524 · EVP, Pres, Central Labs & Intl

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,959.5491

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

SEC source: 0001127602-24-004640 · form4.xml · derivative · entry 3

Caveney Brian J · CIK 0001717915 · EVP, Pres of ED, CMO & CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,296

Underlying: Common Stock · 472 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

F3 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 11, 2023.

F3 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 11, 2023.

F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person.

SEC source: 0001127602-24-004640 · form4.xml · nonDerivative · entry 1

Caveney Brian J · CIK 0001717915 · EVP, Pres of ED, CMO & CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,523.0428

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

SEC source: 0001127602-24-004639 · form4.xml · derivative · entry 3

BERBERIAN LANCE · CIK 0001102900 · EVP, CIO & CTO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,797

Underlying: Common Stock · 324 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

F3 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 11, 2023.

F3 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 11, 2023.

F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person.

SEC source: 0001127602-24-004639 · form4.xml · nonDerivative · entry 1

BERBERIAN LANCE · CIK 0001102900 · EVP, CIO & CTO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,703

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

SEC source: 0001127602-24-004638 · form4.xml · derivative · entry 3

Schroeder Mark S · CIK 0001793112 · EVP, Pres Diagnostics & COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,621

Underlying: Common Stock · 472 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

F3 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 11, 2023.

F3 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 11, 2023.

F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person.

SEC source: 0001127602-24-004638 · form4.xml · nonDerivative · entry 1

Schroeder Mark S · CIK 0001793112 · EVP, Pres Diagnostics & COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,091.1426

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.